<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHAMPHETAMINE HYDROCHLORIDE</span><br/>(meth-am-fet'a-meen)<br/><span class="topboxtradename">Desoxyephedrine, </span><span class="topboxtradename">Desoxyn<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">cerebral stimulant</span>; <span class="classification">anorexiant</span>; <span class="classification">amphetamine</span><br/><b>Prototype: </b>Amphetamine Sulfate<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg tablets; 5 mg, 10 mg, 15 mg long-acting tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Sympathomimetic amine chemically related to amphetamine. CNS stimulant actions approximately equal to those of amphetamine,
         but accompanied by less peripheral activity. However, larger doses produce increased cardiac output, possibly reflex slowing
         of heart rate, and sustained increase in BP, chiefly by cardiac stimulation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>CNS stimulant actions approximately equal to those of amphetamine, but accompanied by less peripheral activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term adjunct in management of exogenous obesity, as adjunctive therapy in attention deficit disorder (ADD), narcolepsy,
         epilepsy, and postencephalitic parkinsonism, and in treatment of certain depressive reactions, especially when characterized
         by apathy and psychomotor retardation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>During pregnancy, especially first trimester (category C), lactation; as anorexiant in children MAO INIBITORS; arteriosclerotic parkinsonism.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Mild hypertension; psychopathic personalities; hyperexcitability states; history of suicide attempts; older adult or debilitated
         patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Attention Deficit Disorder</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>6 y,</i> 2.55 mg 12 times/d, may increase by 5 mg at weekly intervals up to 2025 mg/d<br/><br/><span class="indicationtitle">Obesity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg 13 times/d 30 min before meals or 515 mg of long-acting form once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give early in the day to avoid insomnia, if possible.</li>
<li>Ensure that long-acting tablets are not chewed or crushed; these need to be swallowed whole.</li>
<li>Give 30 min before each meal when used for treatment of obesity. If insomnia results, advise patient to inform physician.</li>
<li>Preserve in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Restlessness, tremor, hyperreflexia, insomnia, headache, nervousness, anxiety, dizziness, euphoria or dysphoria. <span class="typehead">CV:</span> Palpitation, arrhythmias, hypertension, hypotension, <span class="speceff-life">circulatory collapse</span>. <span class="typehead">GI:</span> Dry mouth, unpleasant taste, nausea, vomiting, diarrhea, constipation. <span class="typehead">Special Senses:</span> Increased intraocular pressure. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Acetazolamide,</b> <b>sodium bicarbonate</b> decreases methamphetamine elimination; <b>ammonium chloride,</b> <b>ascorbic acid</b> increases methamphetamine elimination; effects of both methamphetamine and <span class="classification">barbiturates</span> may be antagonized; <b>furazolidone</b> may increase BP effects of <span class="classification">amphetamines</span>interaction may persist for several weeks after discontinuing <b>furazolidone;</b> antagonizes antihypertensive effects of <b>guanethidine,</b> <b>guanadrel;</b> <span class="classification">mao inhibitors</span>, <b>selegiline</b> can cause hypertensive crisis (fatalities reported)do not administer <span class="classification">amphetamines</span> during or within 14 d of administration of these drugs; <span class="classification">phenothiazines</span> may inhibit mood elevating effects of <span class="classification">amphetamines</span>; <span class="classification">tricyclic antidepressants</span> enhance methamphetamine effects because they increase norepinephrine release; <span class="classification">beta-adrenergic agonists</span> increase adverse cardiovascular effects of <span class="classification">amphetamines</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from the GI tract. <span class="typehead">Duration:</span> 612 h. <span class="typehead">Distribution:</span> All tissues especially the CNS; excreted in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Renal elimination. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight throughout period of therapy.</li>
<li>Be alert for paradoxic increase in depression or agitation in depressed patients. Report immediately; drug should be withdrawn.</li>
<li>Do not exceed duration of a few weeks for treatment of obesity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be alert for development of tolerance; happens readily, and prolonged use may lead to drug dependence. Abuse potential is
            high. Methamphetamine is commonly known as "speed" or "crystal" among drug abusers.
         </li>
<li>Withdrawal after prolonged use is frequently followed by lethargy that may persist for several weeks.</li>
<li>Weigh every other day under standard conditions and maintain a record of weight loss.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>